Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 4/20 | 0.60 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.60 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | GGT1 | P19440 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diplosalsalate SCHEMBL3006517 | 0.98 | KDM4E (0.67) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| SCHEMBL3807348 | 0.98 | KDM4E (0.67) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL15391747 | 0.95 | PTGS2 (0.53) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| SCHEMBL2469906 | 0.95 | PTGS2 (0.53) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| Aspirin SCHEMBL28641867 | 0.94 | KDM4E (0.55) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| SCHEMBL2473862 | 0.92 | HSD17B10 (0.57) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| SCHEMBL2471595 | 0.92 | HSD17B10 (0.57) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| Aspirin SCHEMBL2472612 | 0.90 | KDM4E (0.51) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| Citric Acid SCHEMBL28465789 | 0.85 | KDM4E (0.44) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| SCHEMBL3810674 | 0.85 | PTGS2 (0.51) | KDM4EHSD17B10LMNACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4245752-A2 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | Techfields Inc (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | TECHFIELDS PHARMA CO., LTD (CN) | 2023-07-27 | — | — | US | disclosed |
| US-11541029-B2 | High penetration compositions and their applications | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| EP-2170826-B1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | TECHFIELDS INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2021-11-18 | — | — | US | disclosed |
| US-20190152991-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | TECHFIELDS PHARMA CO LTD (CN) | 2019-05-23 | — | — | US | disclosed |
| CN-105669531-B | The prodrug of non-steroidal anti-inflammatory drugs with fast skin and membranes penetration speed and its new medical usage | 于崇曦 | 2019-05-07 | — | — | CN | disclosed |
| US-10233198-B2 | Pro-drugs of NSAIAs with very high skin and membranes penetration rates and their new medicinal uses | TECHFIELDS PHARMA CO., LTD. (CN) | 2019-03-19 | — | — | US | disclosed |
| US-9872846-B2 | High penetration compositions and uses thereof | TECHFIELDS PHARMA CO., LTD. (CN) | 2018-01-23 | — | — | US | disclosed |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | PREMIER RESEARCH INTERNATIONAL, LLC | 2017-07-27 | — | — | US | disclosed |
| CN-105669531-A | Prodrug of non-steroidal anti-inflammatory drug having high skin and biological membrane penetration speed and novel medical application thereof | 于崇曦 | 2016-06-15 | — | — | CN | disclosed |
| CN-101687792-B | Prodrug of non-steroidal anti-inflammatory drug with rapid skin and biological membrane penetration speed and medical application thereof | YU CHONGXI (US) | 2016-03-02 | — | — | CN | disclosed |
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2011-11-03 | — | — | US | disclosed |
| EP-2370406-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | Yu, Chongxi (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100172960-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | PREMIER RESEARCH INTERNATIONAL, LLC | 2010-07-08 | — | — | US | disclosed |
| WO-2010065936-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | YU CHONGXI (US) | 2010-06-10 | — | — | WO | disclosed |
| EP-2170826-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | Techfields Inc (US) | 2010-04-07 | — | — | EP | disclosed |
| CN-101687792-A | Prodrug of non-steroidal anti-inflammatory drug with rapid skin and biological membrane penetration speed and novel medical application thereof | CHONGXI YU | 2010-03-31 | — | — | CN | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
| WO-2008149181-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | TECHFIELDS INC (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152991-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | MYLK2, SLC2A1, SLC2A2 | PTGS2 312/4885PTGS1 418/4885KDM4E 4419/4885 |
| US-10233198-B2 | Pro-drugs of NSAIAs with very high skin and membranes penetration rates and their new medicinal uses | MYLK2, ALPI, SLC2A2 | PTGS2 270/4885PTGS1 368/4885KDM4E 4597/4885 |
| US-20100172960-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | MYLK2, ALPI, SLC2A2 | PTGS2 270/4885PTGS1 368/4885KDM4E 4597/4885 |
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC19A1, HIRA, SLC43A1 | PTGS2 795/4885PTGS1 685/4885KDM4E 4307/4885 |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | PTGS2 7/4885PTGS1 4/4885KDM4E 4795/4885 |
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | PTGS2 7/4885PTGS1 4/4885KDM4E 4795/4885 |
| US-11541029-B2 | High penetration compositions and their applications | SLC19A1, HIRA, SLC43A1 | PTGS2 795/4885PTGS1 685/4885KDM4E 4307/4885 |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC5A7, SLC19A1, SLC43A1 | PTGS2 445/4885PTGS1 332/4885KDM4E 2401/4885 |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | PTGS2 7/4885PTGS1 4/4885KDM4E 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.